INSULIN SUPPLY GAP
Pharma sector: Look beyond the tariff reprieve for generics. 6 mid-cap pharma stocks with an upside potential of more than 23%
With US President Trump, nothing can be ruled out. But, for now at least, Indian pharma companies can breathe a little easier. The 100% tariff shock on pharmaceutical imports into the US from October 1 is limited to patented and branded drugs. Generic drugs have been kept out of it. And the bulk of Indian exports to the world comprise generics. So the threat hanging over pharma companies is gone for now. But, as we said, nothing can be ruled out where Trump is concerned.
Novo Nordisk to phase out key drug, insulin cos spot big biz opportunity
Novo Nordisk is set to discontinue some forms of its Mixtard insulin, including pen and cartridge versions, in India, coinciding with the anticipated launch of its weight-loss drug Wegovy. This move has prompted other major insulin manufacturers like Lupin, Eris, and Eli Lilly to increase their production capabilities to address the potential supply gap.
12 stocks that are BofA Securities' top buys from 7 sectors. Do you own them?
While BofA remained overweight on select domestic cyclicals such as industrials, financials and automobile stocks, it has marginally trimmed its 'overweight' stance on financials, given that while sector earnings visibility remains strong, bankex generally exhibits a strong correlation with the US bank index performance and hence could see some headwinds from negative sentiments on fears of a US recession.
Text of President Joe Biden's State of the Union address
Madam Speaker, Madam Vice President, our First Lady and Second Gentleman. Members of Congress and the Cabinet. Justices of the Supreme Court. My fellow Americans.
What's inside Joe Biden's $1.85T social and climate measure
The bill will still have to clear the Senate, where revisions are nearly certain. But Democrats are aiming to get it to Biden's desk by Christmas. Republicans are lock-step against the measure, leaving Democrats to pass it on their own. Here's what's in the package, based on summaries provided by the White House and the House.
We're here to stay, open to buy right portfolio: Rajiv Malik, President, Mylan
Mylan is committed to staying in India and plans to build up its presence gradually while remaining open to acquisition, says Rajiv Malik.
- Go To Page 1
STMicroelectronics sees huge potential in India's medical devices market: Vivek Sharma
In an interview with ET, Sharma talked about why the changes are important for India and how the firm is moving into this nascent-but-growing market.
Load More
